An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors

References

• Bagatell Hunger R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock J, A, SP, Narendran Rocha A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM. (2007). Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 13:1783–8.
   PubMed Web of Science ®Google Scholar
• Banerji U, Affolter A, Judson I, Marais R, Workman P. (2008). BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 7:737–9.
   PubMed Web of Science ®Google Scholar
• Banerji U, O’donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P, Judson I. (2005). Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152–61.
   PubMed Web of Science ®Google Scholar
• Basso AD, Solit DB, Munster PN, Rosen N. (2002). Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21:1159–66.
   PubMed Web of Science ®Google Scholar
• Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, Norton L, Rosen N, Solit DB. (2008). SNX2112 a synthetic heat shock protein 90 inhibitor has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14:240–8.
   PubMed Web of Science ®Google Scholar
• Chang CL, Tsai YC, He L, Wu TC, Hung CF. (2007). Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70. Cancer Res 67:10047–57.
   PubMed Web of Science ®Google Scholar
• Da Dias S, Friedlos D F, Light Y, Springer C, Workman P, Marais R. (2005). Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65:10686–91.
   PubMed Web of Science ®Google Scholar
• Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D, Rosen N. (2006). V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 103:57–62.
   PubMed Web of Science ®Google Scholar
• Mambula SS, Calderwood SK. (2006). Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes. J Immunol 177:7849–57.
   PubMed Web of Science ®Google Scholar
• Massa C, Guiducci C, Arioli I, Parenza M, Colombo MP, Melani C. (2004). Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70. Cancer Res 64:1502–8.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C. (2006). A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 12:6087–93.
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Trump L, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ. (2005). Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG NSC 330507), a novel inhibitor of heat shock protein 90 in patients with refractory advanced cancers. Clin Cancer Res 11:3385–91.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Tretiakova M, Ma PC, Khaleque MA, Husain AN, Ladanyi A, Chen LB, Bharti A, Salgia R. (2005). Heat shock protein (HSP). Overexpression in lung cancer and potential as a therapeutic target. Proc Am Assoc Cancer Res 46:2387.
   Google Scholar
• Singh-Jasuja H, Hilf N, Scherer HU, Arnold-Schild D, Rammensee HG, Toes RE, Schild H. (2000). The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells. Cell Stress Chaperones 5:462–70.
   PubMed Web of Science ®Google Scholar
• Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM. (2006). Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 47:793–6.
   PubMed Web of Science ®Google Scholar
• Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, Delacruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI. (2007). Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13:1775–82.
   PubMed Web of Science ®Google Scholar
• Srivastava PK, Udono H, Blachere NE, Li Z. (1994). Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39:93–8.
   PubMed Web of Science ®Google Scholar
• Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. (1997). Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117–20.
   PubMed Web of Science ®Google Scholar
• Theriault JR, Adachi H, Calderwood SK. (2006). Role of scavenger receptors in the binding and internalization of heat shock protein 70. J Immunol 177:8604–11.
   PubMed Web of Science ®Google Scholar
• Wang XY, Arnouk H, Chen X, Kazim L, Repasky EA, Subjeck JR. (2006). Extracellular targeting of endoplasmic reticulum chaperone glucose-regulated protein 170 enhances tumor immunity to a poorly immunogenic melanoma. J Immunol 177:1543–51.
   PubMed Web of Science ®Google Scholar
• Weigel BJ, Blaney SM, Reid JM, Safgren SL, Bagatell R, Kersey J, Neglia JP, Ivy SP, Ingle AM, Whitesell L, Gilbertson RJ, Krailo M, Ames M, Adamson PC. (2007). A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children’s Oncology Group study. Clin Cancer Res 13:1789–93.
   PubMed Web of Science ®Google Scholar
• Workman P. (2003). Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2:131–8.
   PubMed Web of Science ®Google Scholar
• Workman P, Burrows F, Neckers L, Rosen N. (2007). Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 1113:202–16.
   PubMed Web of Science ®Google Scholar
• Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, Zhang L, Biamonte M, Brekken J, Lundgren K, Burrows F. (2006). Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 5:1256–64.
   PubMed Web of Science ®Google Scholar